CEP-18770
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CEP-18770, covering 2010-05-20 to 2010-05-20. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Study of the Proteosome Inhibitor CEP 18770 in Patients With Solid Tumours or Non-Hodgkin's Lymphomas [Phase 1]